SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Checkpoint Therapeutics, Inc. (CKPT) , forward earnings yield 26.53%. PEG 0.11 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (35/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 3.8
- PEG Ratio 0.11 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $4.10 (-3.8% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 24/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
35/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CKPT
Valuation Multiples
P/E (TTM)0.0
Forward P/E3.8
PEG Ratio0.11
Forward PEG0.11
P/B Ratio0.00
P/S Ratio4,122.27
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.42
Forward EPS (Est.)$1.13
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield26.53%
Dividend Yield0.00%
Analyst Target$4.10 (-3.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-5.69 |
$590K |
$-13.89M |
-2354.6% |
| 2016 |
$-10.43 |
$2.57M |
$-22.46M |
-874% |
| 2017 |
$-10.03 |
$1.73M |
$-22.68M |
-1314.6% |
| 2018 |
$-12.74 |
$3.51M |
$-36.37M |
-1037.3% |
| 2019 |
$-6.96 |
$1.71M |
$-24.58M |
-1439% |
| 2020 |
$-4.11 |
$1.07M |
$-22.96M |
-2147.9% |
| 2021 |
$-7.45 |
$268K |
$-56.62M |
-21125.7% |
| 2022 |
$-7.57 |
$192K |
$-66.92M |
-34851.6% |
| 2023 |
$-2.77 |
$103K |
$-51.85M |
-50336.9% |
| 2024 |
$-1.42 |
$41K |
$-56.24M |
-137170.7% |
